224 - CURRENT CONTROVERSIES WHEN TREATING PATIENTS WITH CARDIOGENIC SHOCK - POINT AND COUNTERPOINT

Friday, October 25, 2024

9:45 AM – 10:45 AM PT

Room: 211

Workshop Description: Many aspects of cardiogenic shock care continue to be assumed to be beneficial. But the evidence underpinning these management strategies may be lacking. The symposium plans to highlight the expert rationale for routine care options listed in the run of the show. At the end of each 10 min presentation another expert will be allowed to make a brief 5-minute counterpoint and convey to the audience the poor evidence underpinning the management strategy and/or common scenarios where it may not apply.

Interactive and Engagement Activities Description: This symposium is designed to engage all members attending the Canadian Cardiovascular Congress. The chairs will utilize the ARS to engage attendees in two ways. First, at the end of each point and counterpoint, the audience will vote on which strategy they feel is most appropriate in the routine care of patients with cardiogenic shock. Second, the session will highly the exciting contraversies that we experience in looking after patients with cardiogenic shock.

Learning Objectives:

At the end of this session participants will be able to:

critically appraise the literature supporting temporary MCS use in cardiogenic shock;
integrate the rational use of PACs into clinical practice of hemodynamically unstable patients with cardiogenic shock;
appraise the strengths and weaknesses randomized controlled trials of first line vasoactive therapies in patients with shock; and
provide an overview of the effect of positive end expiratory pressure has on cardiovascular hemodynamics.

Disclosure(s):

Filio Billia, MD PhD FRCPC FACC: Abbottt Laboratories: physician-initiated research funding (Ongoing)

Cheryl Peters, MD: No financial relationships to disclose

Erin Rayner-Hartley, MD FRCPC: No financial relationships to disclose

Christopher B. Fordyce, MD: Amgen: Research Grant (Ongoing); Boehringer Ingelheim: Advisor (Ongoing); HLS Therapeutics: Speaker (Ongoing); New Amsterdam: Consultant (Ongoing); Novartis: Consultant (Ongoing), Research Grant (Ongoing); Novo Nordisk: Advisor, Speaker (Ongoing), Consultant (Ongoing), Global Expert Panel (Ongoing); Sanofi: Speaker (Ongoing)

Ansar Hassan, MD: No financial relationships to disclose

Greg Schnell, MD: No financial relationships to disclose

Mustafa Toma, MD FRCPC: No financial relationships to disclose

Anique Ducharme, MD, MSc, FCCS, FACCC: Abbott medical: Co-PI EVOLVE MR trial (Ongoing), Outreach conference in advanced heart failure (Ongoing); Astra-Zeneca: Guidelines conference sponsored by AZ (Ongoing), SYMPHONY trial - earliy detection of heart failure in the community (Ongoing); BridgeBio: Attribute TTR trial (Ongoing); Canadian Heart failure Society: Past president (member of the Executive board, voluntary work) and honorarium for conferences (Ongoing); Merck: National Leader, VITOR trial (Ongoing); Novartis: Guidelines conference sponsored by Novartis (Ongoing), HF-iDOC, PARTHENON (Ongoing); NovoNordisk: Conferences/satellite symposium at HFA (Ongoing), HERMES trial - Member of the steering Committe (Ongoing)

Dave Nagpal, MD, FRCSC: No financial relationships to disclose

Gurmeet Singh, MD: Abbott Medical: Honoraria (Ongoing)

Sean Van Diepen, MD FRCPC: No financial relationships to disclose

Chair(s)

Filio Billia, MD PhD FRCPC FACC

Clinician Scientist
CCS, CCTN, CHFS, CANCARE,CSE
Cheryl Peters, MD

PEDIATRIC CARDIAC ANESTHESIOLOGIST AND INTENSIVIST
CCS, CANCARE, CPCA
BC Children's Hospital

Co-Chair(s)

Erin Rayner-Hartley, MD FRCPC

Cardiology and Critical Care Medicine
Royal Columbian Hospital
University of British Columbia

Presenter(s)

Christopher B. Fordyce, MD (he/him/his)

Associate Professor, UBC Cardiology
CANCARE
Division of Cardiology, University of British Columbia
Ansar Hassan, MD

CARDIAC SURGEON
CCS, CANCARE, CSCS
GS

Greg Schnell, MD

CLINICIAN
CCS, CANCARE, CSE
Libin Cardiovascular Institute
Mustafa Toma, MD FRCPC

Cardiologist
CCS, CCTN, CHFS
University of British Columbia

Planning Committee Member(s)

Anique Ducharme, MD, MSc, FCCS, FACCC (she/her/hers)

Professor of medicine, University of MontrealDirector Heart Failure clinic, Montreal heart Institute
CHFS, CCTN, CANCARE
University of Montreal
DN

Dave Nagpal, MD, FRCSC

Cardiac Surgery / Critical Care Medicine
CCS, CSCS, CANCARE, CCTN
Western University
GS

Gurmeet Singh, MD

CARDIAC SURGEON
CCS, CANCARE, CSCS
CANCARE, CSCS
Sean Van Diepen, MD FRCPC

Associate Professor
University of Alberta
University of Alberta